# AXSM catalysts: Axsome Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/axsm/catalysts

> Axsome Therapeutics, Inc. (AXSM) has 22 upcoming catalysts. The next is the SUNOSI® (solriamfetol) primary completion, December 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Axsome Therapeutics, Inc. |
| Ticker | AXSM (Nasdaq) |
| SEC CIK | 1579428 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/axsm |

## Cash runway

Cash $313.9M as of 2026-09-30; quarterly burn $9.5M; about 99.4 months of runway at that rate (XBRL company facts, accession 0001193125-26-443752).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Aug 2022 | [AUVELITY (dextromethorphan-bupropion) FDA approval](https://sec-api.dev/pdufa/dextromethorphan-bupropion) | AXSM | MDD in adults | completed, approved | "In August 2022, Auvelity® was approved by the FDA for the treatment of MDD in adults and we initiated the commercial launch of Auvelity in the U.S. in October 2022." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1579428/000095017025022457/axsm-20241231.htm)) |
| August 18, 2022 | [Auvelity (bupropion hydrochloride; dextromethorphan hydrobromide) FDA approval](https://sec-api.dev/pdufa/bupropion-dextromethorphan) | AXSM |  | completed, approved | "NDA215430 ORIG-1 (Type 3 - New Dosage Form and Type 4 - New Combination): submission_status AP, submission_status_date 20220818, review_priority PRIORITY; sponsor_name AXSOME; product AUVELITY (BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215430%22)) |
| Sep 2022 | [AUVELITY (dextromethorphan-bupropion) trial start](https://sec-api.dev/pdufa/dextromethorphan-bupropion) | AXSM | AD agitation | completed | "In September 2022, we initiated the ADVANCE-2 study, a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy and safety of AXS-05 in patients with AD agitation." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1579428/000095017025022457/axsm-20241231.htm)) |
| Mar 2024 | [Reboxetine topline data readout](https://sec-api.dev/pdufa/reboxetine) | AXSM |  | completed, positive | "In March 2024, we reported positive topline data from the Phase 3 trial of AXS-12 in narcolepsy, which we call the SYMPHONY study." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1579428/000095017024124758/axsm-20240930.htm)) |
| Q4 2024 | [AXS-07 topline data readout](https://sec-api.dev/pdufa/axs-07) | AXSM |  | scheduled | "Differentiated efficacy and safety profile supported by three Phase 3 clinical trials Ongoing Phase 3 trial evaluating the efficacy and safety of AXS-07 (oral CGRP antagonist non-responders) MOMENTUM Phase 3 (N=1594) Two completed, positive, registrational efficacy and safety trials in >1,800 patients with migraine Rapid, substantial, and sustained pain relief vs. controls in short-term trials AXS-07 well tolerated in open-label extension trial with substantially consistent safety profile as short-term trials Migraine INTERCEPT Phase 3 (N=302) MOVEMENT (OLE) Phase 3 (N=706) PDUFA goal date of January 31, 2025 EMERGE Phase 3 (N=100) Topline Data Anticipated 4Q 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_2.htm)) |
| Q4 2024 | [AUVELITY (dextromethorphan-bupropion) topline data readout](https://sec-api.dev/pdufa/dextromethorphan-bupropion) | AXSM |  | scheduled | "Topline results of ADVANCE-2 and ACCORD-2 Phase 3 trials of AXS-05 in Alzheimer's disease agitation on track for 4Q 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_1.htm)) |
| Q4 2024 | [Reboxetine topline data readout](https://sec-api.dev/pdufa/reboxetine) | AXSM |  | scheduled | "Topline results of ENCORE Phase 3 trial of AXS-12 in narcolepsy on track for 4Q 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_1.htm)) |
| Q4 2024 | [AXS-07 PDUFA date](https://sec-api.dev/pdufa/axs-07) | AXSM |  | scheduled | "Differentiated efficacy and safety profile supported by three Phase 3 clinical trials Ongoing Phase 3 trial evaluating the efficacy and safety of AXS-07 (oral CGRP antagonist non-responders) MOMENTUM Phase 3 (N=1594) Two completed, positive, registrational efficacy and safety trials in >1,800 patients with migraine Rapid, substantial, and sustained pain relief vs. controls in short-term trials AXS-07 well tolerated in open-label extension trial with substantially consistent safety profile as short-term trials Migraine INTERCEPT Phase 3 (N=302) MOVEMENT (OLE) Phase 3 (N=706) PDUFA goal date of January 31, 2025 EMERGE Phase 3 (N=100) Topline Data Anticipated 4Q 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_2.htm)) |
| Nov 2024 | [Esreboxetine NDA/BLA submission](https://sec-api.dev/pdufa/esreboxetine) | AXSM |  | scheduled | "NDA submission for AXS-14 for the management of fibromyalgia anticipated November 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_1.htm)) |
| November 12, 2024 | [Axsome Therapeutics, Inc. earnings report](https://sec-api.dev/companies/axsm/catalysts) | AXSM |  | completed | "Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_1.htm)) |
| Q1 2025 | [Esreboxetine NDA/BLA submission](https://sec-api.dev/pdufa/esreboxetine) | AXSM |  | scheduled | "Fibromyalgia: Axsome plans to submit an NDA to the FDA for AXS-14 for the management of fibromyalgia in the first quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/axsm-ex99_1.htm)) |
| Q1 2025 | [SYMBRAVO® (meloxicam-rizatriptan) topline data readout](https://sec-api.dev/pdufa/meloxicam-rizatriptan) | AXSM | prior inadequate response to oral CGRP inhibitors | scheduled | "Topline results of EMERGE Phase 3 trial of Symbravo in migraine in patients with prior inadequate response to oral CGRP inhibitors on track for 1Q 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/axsm-ex99_1.htm)) |
| Q1 2025 | [SUNOSI® (solriamfetol) topline data readout](https://sec-api.dev/pdufa/solriamfetol) | AXSM | prior inadequate response to oral CGRP inhibitors | scheduled | "NDA submission anticipated in 2H 2025 Topline results of FOCUS and PARADIGM Ph 3 trials of solriamfetol in ADHD and MDD, respectively, on track for 1Q 2025 Topline results from EMERGE Ph 3 trial of Symbravo in migraine in patients with prior inadequate response to oral CGRP inhibitors on track for 1Q 2025 Expanding commercial success Financial strength and operational excellence *Product revenue growth vs. comparable periods in 2023" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/axsm-ex99_2.htm)) |
| Q1 2025 | [Axsome Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/axsm/catalysts) | AXSM |  | scheduled | "The Company is on track to report topline results from the FOCUS Phase 3 trial in the first quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/axsm-ex99_1.htm)) |
| January 13, 2025 | [Axsome Therapeutics, Inc. earnings report](https://sec-api.dev/companies/axsm/catalysts) | AXSM |  | completed | "This announcement is not a comprehensive statement of Axsome's financial results and is subject to completion of Axsome's financial closing procedures." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000095017025004559/axsm-ex99_1.htm)) |
| January 30, 2025 | [SYMBRAVO® (meloxicam-rizatriptan) FDA approval](https://sec-api.dev/pdufa/meloxicam-rizatriptan) | AXSM | central nervous system | completed, approved | "On January 30, 2025, Axsome Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration (FDA) has approved SYMBRAVO® for the acute treatment of migraine with or without aura in adults." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1579428/000095017025011220/axsm-20250130.htm)) |
| January 30, 2025 | [Symbravo (meloxicam; rizatriptan benzoate) FDA approval](https://sec-api.dev/pdufa/meloxicam-rizatriptan-benzoate) | AXSM |  | completed, approved | "NDA215431 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20250130, review_priority STANDARD; sponsor_name AXSOME; product SYMBRAVO (MELOXICAM; RIZATRIPTAN BENZOATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215431%22)) |
| January 31, 2025 | [AXS-07 PDUFA date](https://sec-api.dev/pdufa/axs-07) | AXSM |  | scheduled | "NDA resubmission for AXS-07 for the treatment of migraine accepted by the FDA with PDUFA goal date of January 31, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_1.htm)) |
| Feb 2025 | [SYMBRAVO® (meloxicam-rizatriptan) topline data readout](https://sec-api.dev/pdufa/meloxicam-rizatriptan) | AXSM |  | completed, positive | "Migraine: In February 2025, Axsome announced positive topline results from the EMERGE Phase 3 open-label trial of SYMBRAVO in patients experiencing inadequate response to oral CGRP inhibitors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000095017025063158/axsm-ex99_1.htm)) |
| February 18, 2025 | [Axsome Therapeutics, Inc. earnings report](https://sec-api.dev/companies/axsm/catalysts) | AXSM |  | completed | "Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/axsm-ex99_1.htm)) |
| Mar 2025 | [SUNOSI® (solriamfetol) topline data readout](https://sec-api.dev/pdufa/solriamfetol) | AXSM |  | completed, positive | "Attention Deficit Hyperactivity Disorder: In March 2025, Axsome announced positive topline results from the FOCUS Phase 3 trial evaluating the efficacy and safety of solriamfetol in ADHD in adults." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000095017025063158/axsm-ex99_1.htm)) |
| May 5, 2025 | [Axsome Therapeutics, Inc. earnings report](https://sec-api.dev/companies/axsm/catalysts) | AXSM |  | completed | "Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000095017025063158/axsm-ex99_1.htm)) |
| Jun 2025 | [Esreboxetine NDA/BLA submission](https://sec-api.dev/pdufa/esreboxetine) | AXSM |  | completed | "We have submitted an NDA to the FDA for AXS-14 for the management of fibromyalgia and, in June 2025, announced that we received a Refusal to File letter from the FDA for the NDA." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1579428/000095017025102148/axsm-20250630.htm)) |
| 2H 2025 | [SUNOSI® (solriamfetol) NDA/BLA submission](https://sec-api.dev/pdufa/solriamfetol) | AXSM | prior inadequate response to oral CGRP inhibitors | scheduled | "NDA submission anticipated in 2H 2025 Topline results of FOCUS and PARADIGM Ph 3 trials of solriamfetol in ADHD and MDD, respectively, on track for 1Q 2025 Topline results from EMERGE Ph 3 trial of Symbravo in migraine in patients with prior inadequate response to oral CGRP inhibitors on track for 1Q 2025 Expanding commercial success Financial strength and operational excellence *Product revenue growth vs. comparable periods in 2023" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/axsm-ex99_2.htm)) |
| Q3 2025 | [AUVELITY (dextromethorphan-bupropion) NDA/BLA submission](https://sec-api.dev/pdufa/dextromethorphan-bupropion) | AXSM | Alzheimer's disease agitation | scheduled | "Supplemental NDA submission for AXS-05 in Alzheimer's disease agitation on track for 3Q 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000095017025101624/axsm-ex99_1.htm)) |
| 2H 2025 | [Reboxetine topline data readout](https://sec-api.dev/pdufa/reboxetine) | AXSM |  | scheduled | "NDA submission anticipated in 2H 2025 Positive topline results of third Ph 3 trial of AXS-12 in narcolepsy announced" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/axsm-ex99_2.htm)) |
| August 4, 2025 | [Axsome Therapeutics, Inc. earnings report](https://sec-api.dev/companies/axsm/catalysts) | AXSM |  | completed | "Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000095017025101624/axsm-ex99_1.htm)) |
| Q4 2025 | [Esreboxetine trial start](https://sec-api.dev/pdufa/esreboxetine) | AXSM |  | scheduled | "Fibromyalgia: Axsome plans to initiate a Phase 3, fixed-dose, 12-week, placebo-controlled trial of AXS-14 in fibromyalgia in the fourth quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312525261651/axsm-ex99_1.htm)) |
| Q4 2025 | [AUVELITY (dextromethorphan-bupropion) trial start](https://sec-api.dev/pdufa/dextromethorphan-bupropion) | AXSM |  | scheduled | "Smoking Cessation: Axsome plans to initiate a pivotal Phase 2/3 trial of AXS-05 in smoking cessation in the fourth quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312525261651/axsm-ex99_1.htm)) |
| Q4 2025 | [SUNOSI® (solriamfetol) trial start](https://sec-api.dev/pdufa/solriamfetol) | AXSM |  | scheduled | "Attention Deficit Hyperactivity Disorder: Axsome plans to initiate a Phase 3 trial of solriamfetol in children and adolescents with ADHD in the fourth quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312525261651/axsm-ex99_1.htm)) |
| November 3, 2025 | [Axsome Therapeutics, Inc. earnings report](https://sec-api.dev/companies/axsm/catalysts) | AXSM |  | completed | "Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312525261651/axsm-ex99_1.htm)) |
| December 31, 2025 | [AUVELITY (dextromethorphan-bupropion) NDA/BLA acceptance](https://sec-api.dev/pdufa/dextromethorphan-bupropion) | AXSM | central nervous system | completed | "NEW YORK, December 31, 2025 (Globe Newswire) - Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's supplemental New Drug Application (NDA) for AXS-05 (dextromethorphan HBr and bupropion HCl) for the treatment of Alzheimer's disease agitation, and has granted the application Priority Review designation." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312525337644/axsm-ex99_2.htm)) |
| 2026 | [BAER-101 trial start](https://sec-api.dev/pdufa/azd7325) | AXSM |  | scheduled | "Axsome intends to evaluate AZD7325 as a potential treatment for epilepsy and plans to begin Phase 2 trial-enabling activities in 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm)) |
| Jan 2026 | [Reboxetine NDA/BLA submission](https://sec-api.dev/pdufa/reboxetine) | AXSM | narcolepsy | scheduled | "Axsome anticipates completing the NDA submission in January 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312525337644/axsm-ex99_1.htm)) |
| Jan 2026 | [Esreboxetine trial start](https://sec-api.dev/pdufa/esreboxetine) | AXSM | fibromyalgia | completed | "Fibromyalgia: In January 2026, Axsome initiated the FORWARD study, a Phase 3, double-blind, placebo-controlled, randomized withdrawal trial evaluating the efficacy and safety of AXS-14 for the management of fibromyalgia." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526062421/axsm-ex99_1.htm)) |
| January 12, 2026 | [Axsome Therapeutics, Inc. earnings report](https://sec-api.dev/companies/axsm/catalysts) | AXSM |  | completed | "This announcement is not a comprehensive statement of Axsome's financial results and is subject to completion of Axsome's financial closing procedures." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526009744/axsm-ex99_1.htm)) |
| Feb 2026 | [SUNOSI® (solriamfetol) trial start](https://sec-api.dev/pdufa/solriamfetol) | AXSM | MDD with EDS symptoms | completed | "Major Depressive Disorder: In February 2026, Axsome initiated the CLARITY study, a Phase 3, double-blind, placebo-controlled, multicenter, randomized withdrawal trial evaluating the efficacy and safety of solriamfetol for the treatment of MDD with EDS symptoms." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526202506/axsm-ex99_1.htm)) |
| February 23, 2026 | [Axsome Therapeutics, Inc. earnings report](https://sec-api.dev/companies/axsm/catalysts) | AXSM |  | completed | "Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526062421/axsm-ex99_1.htm)) |
| Q2 2026 | [SUNOSI® (solriamfetol) trial start](https://sec-api.dev/pdufa/solriamfetol) | AXSM |  | scheduled | "Attention Deficit Hyperactivity Disorder: Axsome is on track to initiate two pediatric Phase 3 trials of solriamfetol in ADHD, one in children and one in adolescents, in the second quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526202506/axsm-ex99_1.htm)) |
| April 30, 2026 | [AUVELITY (dextromethorphan-bupropion) label expansion decision](https://sec-api.dev/pdufa/dextromethorphan-bupropion) | AXSM | agitation associated with dementia due to Alzheimer's disease | completed, approved | "AUVELITY was approved by the FDA for the treatment of agitation associated with dementia due to Alzheimer's disease on April 30, 2026 Acceleration in prescription trends among patients aged 65+ following ADA label expansion, alongside continued growth for under 65 FDA approval FDA approval" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526442628/axsm-ex99_2.htm)) |
| April 30, 2026 | [SYMBRAVO® (meloxicam-rizatriptan) PDUFA date](https://sec-api.dev/pdufa/meloxicam-rizatriptan) | AXSM |  | scheduled | "SYMBRAVO® 4Q and full year 2025 net product sales of $4.1 million and $6.6 million, respectively sNDA for AXS-05 for the treatment of Alzheimer's disease agitation granted Priority Review with PDUFA target action date of April 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526062421/axsm-ex99_1.htm)) |
| April 30, 2026 | [AUVELITY (dextromethorphan-bupropion) FDA approval](https://sec-api.dev/pdufa/dextromethorphan-bupropion) | AXSM | agitation associated with dementia due to Alzheimer's disease | completed, approved | "On April 30, 2026, Axsome Therapeutics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (FDA) has approved AUVELITY® for the treatment of agitation associated with dementia due to Alzheimer's disease." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1579428/000119312526197857/axsm-20260430.htm)) |
| April 30, 2026 | [Auvelity (bupropion hydrochloride; dextromethorphan hydrobromide) label expansion decision](https://sec-api.dev/pdufa/bupropion-dextromethorphan) | AXSM |  | completed, approved | "NDA215430 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20260430, review_priority PRIORITY; sponsor_name AXSOME; product AUVELITY (BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215430%22)) |
| April 30, 2026 | [AUVELITY (dextromethorphan-bupropion) PDUFA date](https://sec-api.dev/pdufa/dextromethorphan-bupropion) | AXSM |  | completed, approved | "AXS-05 for Alzheimer's disease agitation, PDUFA target action (April 30, 2026)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526062421/axsm-ex99_1.htm)) |
| May 4, 2026 | [Axsome Therapeutics, Inc. earnings report](https://sec-api.dev/companies/axsm/catalysts) | AXSM |  | completed | "Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526202506/axsm-ex99_1.htm)) |
| Q3 2026 | [AUVELITY (dextromethorphan-bupropion) trial start](https://sec-api.dev/pdufa/dextromethorphan-bupropion) | AXSM |  | scheduled | "Smoking Cessation: Axsome is on track to initiate a pivotal Phase 2/3 trial of AXS-05 in smoking cessation in the third quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/axsm-ex99_1.htm)) |
| 2H 2026 | [SUNOSI® (solriamfetol) topline data readout](https://sec-api.dev/pdufa/solriamfetol) | AXSM | binge eating disorder TAAR1 = Trace amine-associated receptor 1 1 | scheduled | "The Company anticipates topline results from the ENGAGE Phase 3 trial in the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526202506/axsm-ex99_1.htm)) |
| July 15, 2026 | [Reboxetine NDA/BLA acceptance](https://sec-api.dev/pdufa/reboxetine) | AXSM | cataplexy in narcolepsy | completed | "On July 15, 2026, Axsome Therapeutics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1579428/000119312526304039/axsm-20260715.htm)) |
| Aug 2026 | [AUVELITY (dextromethorphan-bupropion) trial start](https://sec-api.dev/pdufa/dextromethorphan-bupropion) | AXSM | smoking cessation | completed | "Smoking Cessation: In August 2026, Axsome initiated the SUMMIT study, a Phase 3, randomized, double-blind, active- and placebo-controlled, multicenter trial to assess the efficacy and safety of AXS-05 for the treatment of smoking cessation." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526442628/axsm-ex99_1.htm)) |
| August 10, 2026 | [Axsome Therapeutics, Inc. earnings report](https://sec-api.dev/companies/axsm/catalysts) | AXSM |  | completed | "Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/axsm-ex99_1.htm)) |
| Q4 2026 | [Axsome Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/axsm/catalysts) | AXSM |  | scheduled | "The Company anticipates topline results from the ENGAGE Phase 3 trial in the fourth quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/axsm-ex99_1.htm)) |
| November 2, 2026 | [Axsome Therapeutics, Inc. earnings report](https://sec-api.dev/companies/axsm/catalysts) | AXSM |  | completed | "Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526442628/axsm-ex99_1.htm)) |
| December 2026 | [SUNOSI® (solriamfetol) primary completion](https://sec-api.dev/pdufa/solriamfetol) | AXSM | Binge-Eating Disorder | scheduled | "NCT06413433 (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06413433)) |
| December 2026 | [SUNOSI® (solriamfetol) primary completion](https://sec-api.dev/pdufa/solriamfetol) | AXSM | Excessive Sleepiness; Shift-work Disorder | scheduled | "NCT06568367 (Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06568367)) |
| Q1 2027 | [SUNOSI® (solriamfetol) topline data readout](https://sec-api.dev/pdufa/solriamfetol) | AXSM | Binge-Eating Disorder | scheduled | "Topline results anticipated 1Q 2027 Solriamfetol inhibits the reuptake of dopamine and norepinephrine, neurotransmitters implicated in the pathophysiology of binge eating disorder1-3 Preclinical and clinical data support potential effects of solriamfetol on appetite, food consumption, and weight4,5 1." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526442628/axsm-ex99_2.htm)) |
| 1H 2027 | [Balipodect trial start](https://sec-api.dev/pdufa/balipodect) | AXSM |  | scheduled | "Schizophrenia: Axsome plans to initiate a pivotal Phase 3 trial of AXS-20 in schizophrenia in the first half of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526442628/axsm-ex99_1.htm)) |
| May 1, 2027 | [Reboxetine PDUFA date](https://sec-api.dev/pdufa/reboxetine) | AXSM | cataplexy in narcolepsy | scheduled | "AXS-12 for cataplexy in narcolepsy, PDUFA target action (May 1, 2027)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526442628/axsm-ex99_1.htm)) |
| 2H 2027 | [Axsome Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/axsm/catalysts) | AXSM |  | scheduled | "The Company anticipates topline results from both studies in the second half of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526442628/axsm-ex99_1.htm)) |
| December 2027 | [SUNOSI® (solriamfetol) primary completion](https://sec-api.dev/pdufa/solriamfetol) | AXSM | Binge-Eating Disorder | scheduled | "NCT06878976 (A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating Disorder): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06878976)) |
| Dec 2027 to Mar 2028 | [SUNOSI® (solriamfetol) topline data readout](https://sec-api.dev/pdufa/solriamfetol) | AXSM | Binge-Eating Disorder | scheduled | "NCT06878976 (A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating Disorder): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06878976)) |
| December 2027 | [Axs-05 (dextromethorphan-bupropion) primary completion](https://sec-api.dev/pdufa/axs-05-dextromethorphan-bupropion) | AXSM | Smoking Cessation | scheduled | "NCT07766655 (Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07766655)) |
| Dec 2027 to Mar 2028 | [Axs-05 (dextromethorphan-bupropion) topline data readout](https://sec-api.dev/pdufa/axs-05-dextromethorphan-bupropion) | AXSM | Smoking Cessation | scheduled | "NCT07766655 (Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07766655)) |
| December 2027 | [SUNOSI® (solriamfetol) primary completion](https://sec-api.dev/pdufa/solriamfetol) | AXSM | ADHD | scheduled | "NCT07773883 (An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07773883)) |
| Dec 2027 to Mar 2028 | [SUNOSI® (solriamfetol) topline data readout](https://sec-api.dev/pdufa/solriamfetol) | AXSM | ADHD | scheduled | "NCT07773883 (An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07773883)) |
| March 2028 | [Axs-14 (esreboxetine) primary completion](https://sec-api.dev/pdufa/axs-14-esreboxetine) | AXSM | Fibromyalgia | scheduled | "NCT07398417 (Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07398417)) |
| Mar to Jun 2028 | [Axs-14 (esreboxetine) topline data readout](https://sec-api.dev/pdufa/axs-14-esreboxetine) | AXSM | Fibromyalgia | scheduled | "NCT07398417 (Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07398417)) |
| May 2028 | [Axs-14 (esreboxetine) primary completion](https://sec-api.dev/pdufa/axs-14-esreboxetine) | AXSM | Fibromyalgia | scheduled | "NCT07637162 (Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07637162)) |
| May to Aug 2028 | [Axs-14 (esreboxetine) topline data readout](https://sec-api.dev/pdufa/axs-14-esreboxetine) | AXSM | Fibromyalgia | scheduled | "NCT07637162 (Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07637162)) |
| Jun to Sep 2028 | [SUNOSI® (solriamfetol) topline data readout](https://sec-api.dev/pdufa/solriamfetol) | AXSM | ADHD | scheduled | "NCT07717879 (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07717879)) |
| Jun to Sep 2028 | [SUNOSI® (solriamfetol) topline data readout](https://sec-api.dev/pdufa/solriamfetol) | AXSM | ADHD | scheduled | "NCT07717892 (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07717892)) |
| June 2028 | [SUNOSI® (solriamfetol) primary completion](https://sec-api.dev/pdufa/solriamfetol) | AXSM | ADHD | scheduled | "NCT07717879 (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07717879)) |
| June 2028 | [SUNOSI® (solriamfetol) primary completion](https://sec-api.dev/pdufa/solriamfetol) | AXSM | ADHD | scheduled | "NCT07717892 (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07717892)) |
| December 2028 | [SUNOSI® (solriamfetol) primary completion](https://sec-api.dev/pdufa/solriamfetol) | AXSM | Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms | scheduled | "NCT07484217 (Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07484217)) |
| Dec 2028 to Mar 2029 | [SUNOSI® (solriamfetol) topline data readout](https://sec-api.dev/pdufa/solriamfetol) | AXSM | Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms | scheduled | "NCT07484217 (Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07484217)) |

## Drugs

- [Axs-05 (dextromethorphan-bupropion)](https://sec-api.dev/pdufa/axs-05-dextromethorphan-bupropion): Smoking Cessation
- [AXS-07](https://sec-api.dev/pdufa/axs-07): 
- [Axs-14 (esreboxetine)](https://sec-api.dev/pdufa/axs-14-esreboxetine): Fibromyalgia
- [BAER-101](https://sec-api.dev/pdufa/azd7325): 
- [Balipodect](https://sec-api.dev/pdufa/balipodect): 
- [Auvelity (bupropion hydrochloride; dextromethorphan hydrobromide)](https://sec-api.dev/pdufa/bupropion-dextromethorphan): 
- [AUVELITY (dextromethorphan-bupropion)](https://sec-api.dev/pdufa/dextromethorphan-bupropion): agitation associated with dementia due to alzheimer's disease, central nervous system, alzheimer's disease agitation, smoking cessation, ad agitation
- [Esreboxetine](https://sec-api.dev/pdufa/esreboxetine): fibromyalgia
- [SYMBRAVO® (meloxicam-rizatriptan)](https://sec-api.dev/pdufa/meloxicam-rizatriptan): prior inadequate response to oral cgrp inhibitors, central nervous system
- [Symbravo (meloxicam; rizatriptan benzoate)](https://sec-api.dev/pdufa/meloxicam-rizatriptan-benzoate): 
- [Reboxetine](https://sec-api.dev/pdufa/reboxetine): cataplexy in narcolepsy, narcolepsy, central nervous system, cataplexy in patients with narcolepsy
- [SUNOSI® (solriamfetol)](https://sec-api.dev/pdufa/solriamfetol): mdd with eds symptoms, prior inadequate response to oral cgrp inhibitors, binge eating disorder taar1 = trace amine-associated receptor 1 1, Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms, Binge-Eating Disorder, Excessive Sleepiness, ADHD

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/axsm/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "AXSM catalysts: Axsome Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/axsm/catalysts

```bibtex
@misc{secapidev_companies_axsm_catalysts_20261116,
  title        = {AXSM catalysts: Axsome Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/axsm/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_axsm_catalysts_20261116","title":"AXSM catalysts: Axsome Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/axsm/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
